Eric Musonza's questions to Kura Oncology Inc (KURA) leadership • Q2 2025
Question
Eric Musonza, on for David Day, asked for more details on how Kyowa Kirin's sales force will aid the commercial launch and how Kura plans to compete with or leapfrog Janssen's Phase 3 trial in frontline AML.
Answer
CCO Brian Powl explained that Kyowa Kirin's team has significant account overlap and will partner with Kura's sales force to provide broader and deeper physician reach. CEO Dr. Troy Wilson addressed the competition by noting Janssen has only initiated one of two planned trials, and Kura is confident it can compete effectively on global enrollment for its COMET-seventeen trials due to overwhelming investigator enthusiasm.